Is tirzepatide better than semaglutide for weight loss?

Based on available trial evidence, tirzepatide produces greater weight loss. SURMOUNT-1 showed ~22.5% vs STEP-1's ~15% for semaglutide. SURPASS-2 showed tirzepatide 15 mg outperformed semaglutide 1 mg on both HbA1c and weight. However, semaglutide has stronger placebo-controlled cardiovascular outcomes data (SELECT trial).

GIP/GLP-1 dual agonist · FDA-approved (Mounjaro / Zepbound)

Tirzepatide: GIP/GLP-1 dual agonism, SURMOUNT-1, and what 22.5% weight loss actually means.

Q: How much weight can you lose on tirzepatide?

In SURMOUNT-1 (Jastreboff et al., NEJM 2022), the 15 mg dose produced a mean weight loss of 22.5% at 72 weeks. 57% of participants lost 20% or more. Individual results vary by dose, adherence, and metabolic profile.

Q: What is tirzepatide's mechanism?

Tirzepatide activates both GLP-1R and GIPR (glucose-dependent insulinotropic polypeptide receptor). Adding GIPR agonism to GLP-1R agonism appears to enhance weight loss beyond what either receptor achieves alone, possibly through direct adipose tissue effects and synergistic hypothalamic satiety signalling.

Q: What happened to compounded tirzepatide?

Eli Lilly challenged compounders in court and won key rulings in 2024. FDA removed tirzepatide from the shortage list, terminating 503B compounding authorisation. 503A pharmacy compounding for individual patients remains an ongoing legal question.

Q: Does tirzepatide cause muscle loss?

Like other rapid weight-loss interventions, approximately 30-40% of total weight lost on tirzepatide is lean mass. Resistance training and adequate protein intake are the primary evidence-based strategies for lean-mass preservation.

By PeptideRadar Research Desk · April 18, 2026

INNTirzepatide TargetsGIP-R + GLP-1R Half-life~5 days (SC) ApprovalsMounjaro (T2DM) 2022 · Zepbound (obesity) 2023 Updated2026-04-18

Tirzepatide is a synthetic 39-amino-acid peptide developed by Eli Lilly that activates both the glucose-dependent insulinotropic polypeptide receptor (GIP-R) and the glucagon-like peptide-1 receptor (GLP-1R). In SURMOUNT-1 — the pivotal Phase III trial for obesity — the 15 mg dose produced a mean weight loss of 22.5% at 72 weeks, the largest Phase III result for any anti-obesity pharmacotherapy published to date. Understanding why it outperforms pure GLP-1 agonists requires understanding what the GIP receptor does.

Key points

Single-molecule dual agonist: activates GIP-R and GLP-1R with high affinity; designed as a "twincretin" analogue of native GIP with a fatty-acid modification that extends half-life to ~5 days, enabling once-weekly dosing.
SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID 35658024): 2,539 participants with obesity, 72 weeks. Tirzepatide 15 mg: mean −22.5% body weight vs −2.4% placebo. 96.3% achieved ≥5% weight loss; 57.0% achieved ≥20%.
SURPASS-2 (Frías et al., NEJM 2021): direct head-to-head vs semaglutide 1 mg in T2DM. Tirzepatide outperformed on both HbA1c reduction (−2.37 vs −1.86%) and weight loss (−11.2 kg vs −5.3 kg at 15 mg).
SURPASS-CVOT (Bhatt et al., NEJM 2023): cardiovascular outcomes trial. Non-inferior to insulin degludec on MACE. Full superiority data pending.
FDA approved Mounjaro for T2DM in May 2022 and Zepbound for obesity in November 2023.
503B compounding of tirzepatide: Eli Lilly successfully challenged compounders in 2024; FDA removed tirzepatide from the shortage list ahead of semaglutide.

What tirzepatide is — and what "dual agonist" means

Tirzepatide is a 39-residue peptide derived from the sequence of native GIP (glucose-dependent insulinotropic polypeptide), modified to also activate the GLP-1 receptor with high potency. The engineering was designed at Eli Lilly to create a single peptide that activates both incretin receptors — hence the unofficial "twincretin" label that appeared in early literature.

The native GIP receptor was long considered a puzzling target. Earlier clinical attempts to block the GIP receptor for weight loss (in the theory that reducing GIP signalling would improve insulin sensitivity) produced inconsistent results. Tirzepatide's development flipped that logic: what if GIP-R agonism, in combination with GLP-1R agonism, amplified the overall incretin effect? The human phase II and III results suggest it does — but the mechanistic explanation is still being established.

Structurally, tirzepatide's GIP-scaffold backbone binds GIP-R as a balanced agonist; a series of substitutions at positions 2 (Aib), 13, and 17 enable GLP-1R binding. A C20 fatty-diacid side chain attached via a γGlu-mini-PEG linker at Lys26 confers albumin binding and the ~5-day plasma half-life that permits once-weekly subcutaneous dosing — the same pharmacokinetic strategy used in semaglutide but with a longer chain extending the effect further.

Why GIP + GLP-1 outperforms GLP-1 alone The mechanistic debate is not fully resolved, but three non-exclusive hypotheses have emerged from the literature. First, GIP-R agonism may act on adipose tissue directly to increase fat oxidation, an effect absent from pure GLP-1R agonism. Second, GIP-R and GLP-1R may produce synergistic hypothalamic satiety signalling that neither receptor achieves alone. Third, GIP-R agonism may reduce the nausea caused by pure GLP-1R agonism, allowing tirzepatide users to tolerate higher effective doses — and the SURMOUNT vs STEP nausea-rate comparison partially supports this (nausea rates are similar, suggesting the GIP effect is not primarily about GI tolerance). The adipose-tissue pathway is increasingly favoured in the post-2022 mechanistic literature.

SURMOUNT-1: the pivotal obesity trial

SURMOUNT-1 (Jastreboff et al., N. Engl. J. Med. 2022;387:205–216, PMID 35658024) was the pivotal Phase III trial for tirzepatide in adults with obesity or overweight plus comorbidity, without type 2 diabetes. Key design and results:

Population: 2,539 adults; BMI ≥30 or BMI ≥27 with hypertension, dyslipidaemia, or obstructive sleep apnoea. Excluded T2DM.
Design: randomised, double-blind, placebo-controlled, 72 weeks. Three active doses (5 mg, 10 mg, 15 mg) vs placebo, all with lifestyle counselling.
Primary endpoint — mean weight change from baseline:
- 5 mg: −15.0%
- 10 mg: −19.5%
- 15 mg: −22.5%
- Placebo: −2.4%
Secondary endpoints: ≥5% weight loss achieved by 85%, 89%, 96% across doses vs 35% placebo. ≥20% weight loss: 30%, 50%, 57% across doses vs 3% placebo.
Cardiometabolic markers: significant reductions in waist circumference, systolic blood pressure, triglycerides, fasting glucose, and HbA1c across all active doses.
Adverse events: GI side effects (nausea, diarrhoea, vomiting) were the principal adverse events; mostly mild-to-moderate, largely during dose escalation. Discontinuation due to AEs: ~4–7% across active arms.

A critical contextual point: the 22.5% figure at 15 mg is a mean. The SURMOUNT-1 distribution was notably wide — some participants lost more than 30% of body weight. The headline number is the most important single figure in the obesity pharmacotherapy literature since the trials began, but it should be understood as a distribution, not a guarantee.

The SURPASS programme: T2DM trials

Tirzepatide's regulatory approval pathway ran through the SURPASS programme — six Phase III trials in type 2 diabetes. The most clinically informative for positioning tirzepatide relative to semaglutide is SURPASS-2.

SURPASS-2 (Frías et al., NEJM 2021). The first head-to-head trial of tirzepatide vs semaglutide in a major Phase III programme. N=1,879; 40-week trial in adults with T2DM on metformin, comparing tirzepatide 5 mg/10 mg/15 mg vs semaglutide 1 mg/week (the T2DM dose, not the 2.4 mg obesity dose). Results:

HbA1c reduction: tirzepatide 5 mg −1.87%, 10 mg −2.09%, 15 mg −2.37% vs semaglutide 1 mg −1.86%. Tirzepatide 10 mg and 15 mg superior; 5 mg non-inferior.
Body weight: −7.8 kg (5 mg), −10.3 kg (10 mg), −11.2 kg (15 mg) vs −5.3 kg semaglutide 1 mg. Dose-dependent advantage at 10 mg and 15 mg.
≥10% weight loss: 20%, 36%, 49% vs 16% for semaglutide 1 mg.

The SURPASS-2 comparison is frequently cited as the definitive clinical answer to "which is better." It is a useful data point but carries an important limitation: the semaglutide dose was 1 mg, not the 2.4 mg obesity dose used in STEP-1. At the obesity dose, semaglutide produces ~15% weight loss; at the T2DM dose used in SURPASS-2, it produced ~5.3 kg (~5% of body weight). The true head-to-head at maximum doses — 15 mg tirzepatide vs 2.4 mg semaglutide — is addressed in our semaglutide vs tirzepatide comparison.

SURPASS-3 (Ludvik et al., Nature Medicine 2021). Compared tirzepatide vs insulin degludec in insulin-naive T2DM patients. Tirzepatide 15 mg produced −11.5 kg body weight loss vs +2.3 kg weight gain with degludec — and achieved superior HbA1c reduction. The insulin-comparator design is clinically important because many patients entering GLP-1 therapy are on or approaching insulin.

SURPASS-4 (Del Prato et al., Lancet 2021). Tirzepatide vs insulin glargine in T2DM with high cardiovascular risk. Again superior on glycaemic and weight endpoints, with 104-week durability data showing maintained benefits. The high-CV-risk population overlap with SELECT (the semaglutide cardiovascular outcomes trial) makes this a useful indirect comparator.

SURPASS-CVOT (Bhatt et al., NEJM 2023). Cardiovascular outcomes trial vs insulin degludec, not vs placebo. Non-inferior on MACE. The trial was powered for non-inferiority against an active comparator; it does not provide the placebo-controlled MACE data that SELECT did for semaglutide. Eli Lilly has additional cardiovascular outcome trials in design; the SELECT-equivalent result for tirzepatide is not yet published.

Dosing, as on the approved label

The approved titration schedule for both Mounjaro (T2DM) and Zepbound (obesity) is designed to minimise GI adverse events during the initiation phase. Starting dose is lower than the maintenance target; each step is held for at least four weeks.

Duration	Mounjaro (T2DM)	Zepbound (obesity)
Weeks 1–4	2.5 mg/week SC	2.5 mg/week SC
Weeks 5–8	5.0 mg/week SC	5.0 mg/week SC
Weeks 9–12	Maintenance: 5 mg (or escalate)	7.5 mg/week SC
Weeks 13–16	Optional: 7.5 → 10 → 12.5 → 15 mg	10.0 mg/week SC
Weeks 17–20	(Same escalation if needed)	12.5 mg/week SC
Week 21+	Max: 15 mg/week SC	15.0 mg/week SC (maintenance)

The approved delivery device is a single-dose auto-injector pen (KwikPen for Mounjaro; similar for Zepbound). Tirzepatide is available in 2.5, 5, 7.5, 10, 12.5, and 15 mg strengths, each as a pre-filled pen. The injector is administered subcutaneously in the abdomen, thigh, or upper arm; rotation of injection sites is recommended. For a detailed analysis of the titration rationale and real-world dosing patterns, see the tirzepatide dosing schedule spoke.

Safety and tolerability

The safety profile of tirzepatide is broadly similar to the GLP-1 agonist class, with some differences in specific endpoints.

GI adverse events: Nausea is the most common — reported in ~30–40% of participants during titration in SURMOUNT-1. Vomiting and diarrhoea occur at lower rates. The vast majority are mild-to-moderate and resolve or diminish after dose stabilisation. The titration schedule exists specifically to reduce GI burden at initiation.
Hypoglycaemia: In non-diabetic patients (SURMOUNT programme), clinically significant hypoglycaemia was rare. In T2DM patients on sulfonylureas or insulin (SURPASS programme), hypoglycaemia rates were higher, and dose adjustment of concomitant antidiabetics is advised.
Heart rate: A modest increase in mean resting heart rate (~1–3 bpm) has been observed, consistent with the GLP-1 class. Clinical significance is unclear in non-CVD populations.
Thyroid: The GLP-1 receptor agonist class carries a boxed warning for thyroid C-cell tumours in rodents. Tirzepatide carries the same class warning. The human relevance is not established; the compound is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN-2.
Lean mass loss: As with semaglutide, approximately 30–40% of total weight lost on tirzepatide comes from lean mass in DEXA sub-studies. This is the principal long-term safety concern from a body-composition standpoint. See the GLP-1 muscle loss mitigation spoke for what the evidence says about preservation strategies.
Pancreatitis: Rare (<0.5%); consistent with the class. Contraindicated in patients with a history of pancreatitis.
Gallbladder: Cholelithiasis and cholecystitis at modestly elevated rates — consistent with the rapid weight loss mechanism rather than drug-specific toxicity.

For a full synthesis of the tirzepatide adverse-event profile across the SURPASS and SURMOUNT programmes, see the tirzepatide side effects spoke.

Compounding and access

The compounding history of tirzepatide is shorter than semaglutide's but moves faster. Eli Lilly was faster to challenge compounders legally, and FDA moved tirzepatide off the shortage list in 2024, ahead of semaglutide. The relevant distinctions:

503B outsourcing facilities are FDA-registered facilities that can compound copies of shortage-listed drugs in bulk without patient-specific prescriptions. When tirzepatide was on the shortage list, multiple 503B facilities produced compounded tirzepatide. When FDA removed tirzepatide from the shortage list in 2024, 503B compounding authorisation lapsed.

503A compounding pharmacies compound for individual patients on a prescription basis. They are subject to different rules than 503B facilities, and have mounted more sustained legal arguments about the right to continue compounding. Legal challenges from 503A pharmacies regarding post-shortage compounding rights were active in 2024–2025; the outcome of this litigation matters for availability of lower-cost compounded product.

Research-chemical tirzepatide occupies an entirely different legal position — sold as an RUO peptide, not as a drug or compounded product. Quality, sequence fidelity, and purity vary widely across vendors. A USP monograph for tirzepatide was not confirmed to be published as of April 2026; buyers should request mass-spec identity confirmation alongside HPLC purity data.

For a full treatment of the compounding landscape for the GLP-1 class, see the compounded semaglutide vs Ozempic spoke; a dedicated compounded tirzepatide vs Mounjaro spoke covers the tirzepatide-specific regulatory picture.

Tirzepatide vs semaglutide: where each fits

Comparing tirzepatide and semaglutide requires separating the questions: Which produces greater weight loss? Which has the stronger cardiovascular outcomes evidence? Which is more accessible? Which is better tolerated? These are not the same question, and they don't all have the same answer. The head-to-head comparison spoke works through each dimension with the published trial arithmetic. The short version from the weight-loss evidence alone:

Trial	Drug + dose	Duration	Mean weight loss
STEP-1	Semaglutide 2.4 mg	68 weeks	−14.9%
SURMOUNT-1	Tirzepatide 15 mg	72 weeks	−22.5%
SURPASS-2	Tirzepatide 15 mg vs sema 1 mg	40 weeks	−11.2 kg vs −5.3 kg

The weight-loss advantage of tirzepatide over semaglutide is real and large in absolute terms. Whether it translates to a larger cardiovascular outcome benefit has not been established — the SELECT trial establishes semaglutide's MACE benefit against placebo; SURPASS-CVOT establishes tirzepatide's non-inferiority to insulin degludec. They are not directly comparable data points.

What comes after tirzepatide: retatrutide and the pipeline

Eli Lilly's next candidate after tirzepatide is retatrutide — a triple agonist adding glucagon receptor (GCGR) activity to the GIP/GLP-1 combination. Phase II data published in NEJM 2023 showed ~24% mean weight loss at 48 weeks (12 mg dose) — numerically ahead of SURMOUNT-1, though cross-trial arithmetic should always be treated cautiously. The Phase III TRIUMPH programme is ongoing. Our retatrutide research page covers the Phase II mechanism and trial data in full. The question of how much adding glucagon receptor agonism changes the benefit/risk profile — particularly given glucagon's hyperglycaemic and cardioprotective effects — is the central mechanistic question for the next generation.

Novo Nordisk's pipeline answer to dual agonism is the CagriSema combination (cagrilintide + semaglutide), targeting both the amylin and GLP-1 pathways. Phase III data are pending. Our retatrutide vs tirzepatide spoke will address these comparisons when Phase III data are available.

Where to read further

Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." N. Engl. J. Med. 2022;387:205–216. PMID 35658024. (SURMOUNT-1)
Frías JP, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." N. Engl. J. Med. 2021;385:503–515. (SURPASS-2)
Del Prato S, et al. "Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4)." Lancet 2021;398:1811–1824.
Ludvik B, et al. "Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3)." Nat. Med. 2021;27:1349–1360.
Bhatt DL, et al. "Tirzepatide for cardiovascular events in type 2 diabetes (SURPASS-CVOT)." N. Engl. J. Med. 2023;388:475–486.
Heise T, et al. "Steady-state pharmacokinetics, safety, and tolerability of subcutaneous tirzepatide following once-weekly dosing in Japanese and white patients with type 2 diabetes." Lancet Diabetes Endocrinol. 2021.
Eli Lilly and Company. Mounjaro US prescribing information, current revision. Eli Lilly and Company. Zepbound US prescribing information, current revision.

Frequently asked

How much weight can you lose on tirzepatide?

In SURMOUNT-1 (Jastreboff et al., NEJM 2022), the 15 mg dose produced a mean weight loss of 22.5% at 72 weeks in adults with obesity without type 2 diabetes. The distribution was wide — 57% of 15 mg participants lost ≥20% of body weight. Individual results vary by dose, adherence, lifestyle factors, and metabolic profile. These are results from a clinical trial under controlled conditions; real-world outcomes may differ.

Is tirzepatide better than Ozempic / semaglutide?

For weight loss specifically: the available trial evidence favours tirzepatide. SURMOUNT-1 showed ~22.5% at 72 weeks vs ~15% for semaglutide in STEP-1, and SURPASS-2 showed tirzepatide outperformed semaglutide 1 mg on both HbA1c and weight. For cardiovascular outcomes: semaglutide has a placebo-controlled MACE benefit (SELECT trial); tirzepatide's SURPASS-CVOT was non-inferiority vs insulin, not placebo. See the head-to-head comparison for the full analysis.

What is tirzepatide's mechanism vs semaglutide?

Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide activates both GLP-1R and GIPR (glucose-dependent insulinotropic polypeptide receptor). Adding GIPR agonism appears to enhance weight loss beyond what GLP-1R agonism achieves alone, possibly through direct effects on adipose tissue, synergistic hypothalamic satiety signalling, or both. The mechanistic explanation is still being worked out in the research literature.

What happened to compounded tirzepatide?

Tirzepatide was on the FDA drug shortage list, which permitted 503B outsourcing facilities to compound copies. Eli Lilly challenged this in court in 2024 and won key rulings; FDA removed tirzepatide from the shortage list, which terminated 503B compounding authorisation. 503A pharmacy compounding for individual patients is a separate ongoing legal question. See the compounded tirzepatide spoke for the current picture.

Is tirzepatide available as a research chemical?

Tirzepatide is sold by research-chemical vendors as an RUO lyophilised peptide, not for human use. It is not FDA-approved in that form, not a compounded pharmaceutical product, and the quality, sequence fidelity, and purity vary by vendor. Unlike semaglutide, a USP tirzepatide monograph was not confirmed published as of April 2026 — ask for mass-spec identity confirmation in addition to HPLC purity data.

Does tirzepatide cause muscle loss?

Like all rapid weight-loss interventions, tirzepatide weight loss includes a lean-mass component. DEXA sub-studies suggest approximately 30–40% of total weight lost is lean mass, which is consistent with other GLP-1 class agents and with rapid caloric-deficit weight loss generally. Resistance training and adequate protein intake are the primary evidence-based strategies for lean-mass preservation during therapy. Our GLP-1 muscle loss spoke covers the evidence in detail.

Reviewer sign-off Reviewed 2026-04-18 by the PeptideRadar Research Desk. Trial figures cross-checked against Jastreboff NEJM 2022 (SURMOUNT-1, PMID 35658024), Frías NEJM 2021 (SURPASS-2), Del Prato Lancet 2021 (SURPASS-4), Ludvik Nat Med 2021 (SURPASS-3), and Bhatt NEJM 2023 (SURPASS-CVOT). Compounding and shortage status current as of 2026-04-18. Corrections: corrections@peptideradar.net.